Integra LifeSciences (IART) reported Q4 adjusted earnings Tuesday of $0.97 per diluted share, up from $0.89 a year earlier.

Analysts polled by FactSet expected $0.85.

Revenue for the quarter ended Dec. 31 was $442.6 million, up from $397.0 million a year earlier.

Analysts surveyed by FactSet expected $445.1 million.

For Q1, the biopharmaceutical company expects adjusted diluted EPS of $0.40 to $0.45 on revenue of $375 million to $385 million. Analysts polled by FactSet expect non-GAAP EPS of $0.56 on revenue of $411.7 million.

For 2025, the company expects adjusted diluted EPS of $2.41 to $2.51 on revenue of $1.65 billion to $1.72 billion. Analysts polled by FactSet expect non-GAAP EPS of $2.51 on revenue of $1.71 billion.

Shares of the company were down more than 2% in recent premarket activity.